AVITA Medical, Inc. (RCEL) Discusses Advanced Wound Care Solutions and Data-Driven Approaches in Clinical Healing Transcript
AVITA Medical, Inc. ( RCEL ) Discusses Advanced Wound Care Solutions and Data-Driven Approaches in Clinical Healing November 12, 2025 5:00 PM EST Company Participants Ben Atkins - Vice President of Investor Relations & Corporate Communications Cary Vance - Independent Non-Executive Chairman & Interim CEO Presentation Ben Atkins Vice President of Investor Relations & Corporate Communications [Audio Gap] Cary Vance Independent Non-Executive Chairman & Interim CEO [Audio Gap] In each case, we believe our products are best from a clinical perspective, but also that they speed up the time to graft, the time to heal, which is extremely important for the patient and potential complications, but also important for the hospital that is trying to -- that is striving to make economic progress themselves. And so PermeaDerm is a biosynthetic dressing that protects the wound, that stabilizes the wound.
AVITA Medical, Inc. (RCEL) Q3 2025 Earnings Call Transcript
AVITA Medical, Inc. ( RCEL ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Ben Atkins - Vice President of Investor Relations & Corporate Communications Cary Vance - Independent Non-Executive Chairman & Interim CEO David OToole - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald & Co., Research Division Joshua Jennings - TD Cowen, Research Division Chris Kallos - MST Financial Services Pty Limited, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the AVITA Medical, Inc. Third Quarter 2025 Earnings Conference Call.
AVITA Medical, Inc. (RCEL) Q2 2025 Earnings Call Transcript
AVITA Medical, Inc. (NASDAQ:RCEL ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Ben Atkins - Corporate Participant David O'Toole - Chief Financial Officer James M. Corbett - CEO, President & Executive Director Conference Call Participants Joshua Thomas Jennings - TD Cowen, Research Division Ross Everett Osborn - Cantor Fitzgerald & Co., Research Division Operator Good day, and thank you for standing by.
AVITA Medical, Inc. (RCEL) Q1 2025 Earnings Call Transcript
AVITA Medical, Inc. (NASDAQ:RCEL ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Jessica Ekeberg - Director, Investor Relations Jim Corbett - Chief Executive Officer David O'Toole - Chief Financial Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Chris Kallos - MST Access Operator Good day, and thank you for standing by. Welcome to AVITA Medical First Quarter 2025 Earnings Conference Call.
Wall Street Analysts Predict a 52.64% Upside in Avita Medical (RCEL): Here's What You Should Know
The mean of analysts' price targets for Avita Medical (RCEL) points to a 52.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
After Sales Rebound In January, AVITA Is Set Up For A Monster Year
After Sales Rebound In January, AVITA Is Set Up For A Monster Year
AVITA Medical, Inc. (RCEL) Q4 2024 Earnings Call Transcript
AVITA Medical, Inc. (NASDAQ:RCEL ) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Jessica Ekeberg - Director of Investor Relations Jim Corbett - Chief Executive Officer David O'Toole - Chief Financial Officer Conference Call Participants Matthew Park - Cantor Fitzgerald Ryan Zimmerman - BTIG Brooks O'Neil - Lake Street Capital Markets Joshua Jennings - TD Cowen Operator Good day, and thank you for standing by. Welcome to the AVITA Medical Fourth Quarter 2024 Earnings Conference Call.
Investors Burned By AVITA Medical's Sales Miss: I'm Even More Bullish
AVITA Medical's stock plummeted 36.4% after a significant Q4 sales miss, highlighting a pattern of guidance misses. Management's breakeven target shifted to Q4 2025. It also gave 2025 sales guidance of $100-$106 million. The Company will be forced to repay its $40 million OrbiMed loan if its sales follow my projections and company guidance.
AVITA Medical: A Dip Buy As 2025 Looks Bullish With Cohealyx And RECELL GO Mini
AVITA Medical: A Dip Buy As 2025 Looks Bullish With Cohealyx And RECELL GO Mini
Avita Medical Cuts Annual Sales Forecast On Softer Demand From Hospitals
On Tuesday, Avita Medical, Inc. RCEL revised its revenue guidance for the fourth quarter and full year of 2024.
Avita Medical price target lowered to $14 from $20 at Lake Street
Lake Street analyst Brooks O'Neil lowered the firm's price target on Avita Medical to $14 from $20 and keeps a Buy rating on the shares after the company announced preliminary Q4 commercial revenue that was below the firm's estimate and consensus and management lowered the expected FY24 revenue outlook. The company also provided initial FY25 revenue guidance that was below the firm's previous revenue estimate, which Lake Street calls "disappointing." However, with shares off nearly 22% in the after hours, the firm is maintaining a Buy rating as it continues to think this is a significant year for Avita, the analyst added.
AVITA Medical's shares sink 19% after another forecast cut
AVITA Medical's Australia-listed shares sank nearly 19% on Wednesday, set for their worst day in 15 months, after the regenerative medicine firm cut its forecast for the fourth time in five quarters and pushed out its profitability target.
